Insider transactions
Mary T. Szela, who serves as Chief Executive Officer and President of TriSalus Life Sciences, Inc. (NASDAQ: TLSI), carried out two separate share dispositions in March that together total 20,302 common shares. The sales were executed at prices between $3.85 and $4.13 per share, yielding proceeds of $79,382.
On March 11, 2026, Szela sold 4,358 shares at $4.13 per share. After that transaction she directly held 768,931 TriSalus shares. A second sale followed on March 17, 2026, when she disposed of 15,944 shares at $3.85 per share, leaving her with a direct ownership stake of 752,987 shares.
The company’s stock was trading at $3.92 at the time of these disclosures, marking a 45% decline year-to-date and sitting close to its 52-week low of $3.42. An InvestingPro analysis included in the disclosures indicated the shares appear undervalued at current levels, and noted that TriSalus’ next earnings release is scheduled for March 26. The analysis and the Pro Research Report covering TLSI and more than 1,400 other U.S. equities were cited as additional resources for investors.
Reason for the sales
The filings state the dispositions were executed to cover tax obligations related to the vesting of restricted stock units. The company noted these sales do not constitute discretionary transactions by Szela.
Recent financial and clinical developments
TriSalus reported a notable increase in revenue in the fourth quarter of 2025, with sales of $13.2 million, representing a 60% year-over-year rise. Management attributed that growth to improved manufacturing efficiencies and a strategic expansion of the product portfolio. Despite the higher revenue, the company posted a net operating loss of $3.3 million for the quarter, an improvement from the $7.6 million operating loss recorded in the same quarter a year earlier.
For fiscal 2025 as a whole, TriSalus reported total revenue of $45 million, a 53% increase versus the prior fiscal year.
Following the earnings release, Jones Trading reiterated a Buy rating on TriSalus stock and set a price target of $11.00. Jones Trading also conducted a follow-up call with company management to review the results.
On the scientific front, TriSalus released preclinical data examining its Pressure-Enabled Drug Delivery technology. The study evaluated delivery of nelitolimod in liver tumor models and compared the novel delivery approach with conventional methods, using both porcine and murine liver tumor systems.
What this means for stakeholders
The insider transactions were transaction-specific and tied to RSU tax liabilities, according to company disclosures. Separately, TriSalus’ topline momentum and improved operating loss provide context for ongoing analyst coverage and market interest, while the preclinical work highlights continued R&D activity in delivery technologies aimed at oncology targets.
Investors and market participants awaiting the company’s next quarterly report on March 26 will have an updated set of operational and financial metrics to assess alongside the recent insider filings and clinical program updates.